Dexcom (DXCM) Long-Term Deferred Tax (2020 - 2026)

Dexcom (DXCM) has reported Long-Term Deferred Tax for 7 consecutive years, with $304.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Long-Term Deferred Tax fell 38.73% year-over-year to $304.1 million in Q2 2026; TTM through Jun 2026 was $304.1 million, a 38.73% decrease from a year earlier, with the FY2025 full-year figure at $295.6 million, down 38.57% from the prior year.
• Long-Term Deferred Tax was $304.1 million for Q2 2026 at Dexcom, up from $296.1 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $501.3 million in Q3 2023 and troughed at $290.8 million in Q1 2022.
• A 5-year average of $396.1 million and a median of $396.3 million in 2023 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax soared 58.25% in 2022 and tumbled 39.24% in 2026, its largest moves.
• Over 5 years, Long-Term Deferred Tax stood at $341.2 million in 2022, then climbed by 22.92% to $419.4 million in 2023, then advanced by 14.74% to $481.2 million in 2024, then slumped by 38.57% to $295.6 million in 2025, then increased by 2.88% to $304.1 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $304.1 million (Q2 2026), $296.1 million (Q1 2026), and $295.6 million (Q4 2025), per Business Quant data.